{"id":10348,"date":"2026-10-06T06:40:29","date_gmt":"2026-10-06T11:40:29","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10348"},"modified":"2026-10-06T06:53:10","modified_gmt":"2026-10-06T11:53:10","slug":"nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/","title":{"rendered":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0633\u062a\u0634\u0627\u0631\u0643 \u0641\u064a \u0645\u0624\u062a\u0645\u0631 \u0622\u064a\u0633\u064a\u0644\u064a\u0631\u064a\u062a\u0648\u0631 2026 \u0648\u0627\u0644\u0627\u062c\u062a\u0645\u0627\u0639 \u0627\u0644\u0633\u0646\u0648\u064a \u0644\u0644\u0623\u0643\u0627\u062f\u064a\u0645\u064a\u0629 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646 2026"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10348\" class=\"elementor elementor-10348\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><em>Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY<sup>\u00ae<\/sup>in the Retina Drug Delivery New Targets Showcase at Eyecelerator 2026.<\/em><\/li><li><em>Four-year REMAIN data from the RESTORE Phase 2b\/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting, October 8\u201313, 2026, in New Orleans, Louisiana.<\/em><\/li><\/ul><p><span class=\"legendSpanClass\">\u062f\u0627\u0644\u0627\u0633<\/span>, <span class=\"legendSpanClass\">Oct. 6, 2026<\/span> \/ \u0628\u064a \u0622\u0631 \u0646\u064a\u0648\u0632\u0648\u0627\u064a\u0631 \/ \u2014 <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4790502-1&amp;h=526406892&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fnanostherapeutics.com%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDpkNzJiMjllNGViNWQ1OGUxMDcwZWI4MWE0YWExNTExOTo3OjBlNjE6NDIzZWQ3ZWEzYmJkYTFlYWRhMTQ0ODVkZjJhMmFlODEyMGJiOGE4MWI0ZjhkMGUzMjg3YWRjNzhkNWFiOTBmMzpwOlQ6Rg&amp;a=Nanoscope+Therapeutics\" target=\"_blank\" rel=\"nofollow noopener\">\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<\/a>, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that its optogenetics gene therapy (MOGENRY, MCO-010) will be featured in various scientific programming\u00a0at the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4790502-1&amp;h=2008657513&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.aao.org%2Fannual-meeting___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDpkNzJiMjllNGViNWQ1OGUxMDcwZWI4MWE0YWExNTExOTo3Ojg2ZmQ6NjYxMzFjYzYyZDVmODczYjc1Y2I0MzI5ZDA2MTNmOWZhN2FjMTA5NTg3ZjMxNTkyMGRmYjNmYTJkN2U4YzFhZDpwOlQ6Rg&amp;a=American+Academy+of+Ophthalmology+(AAO)+2026\" target=\"_blank\" rel=\"nofollow noopener\">American Academy of Ophthalmology (AAO) 2026<\/a>\u00a0annual meeting taking place October 8\u201313, 2026,\u00a0in New Orleans. Additionally, the company will participate in <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4790502-1&amp;h=2247113537&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Feyecelerator.com%2F___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDpkNzJiMjllNGViNWQ1OGUxMDcwZWI4MWE0YWExNTExOTo3OmMwZTA6ZDEyZjZkOWU5NzQ5MGFkZTE1MzFiMDA0ZmVlNzc4MGU5ZTYzY2VlYTliOGRlOGRhOWFiZWJjOWFiZjJiOWI4MDpwOlQ6Rg&amp;a=Eyecelerator%40AAO+2026\" target=\"_blank\" rel=\"nofollow noopener\">Eyecelerator@AAO 2026<\/a>\u00a0with a company presentation and panel participation. Eyecelerator brings together ophthalmic innovators, industry leaders, clinicians, and investors to accelerate the development of new therapies and technologies in eye care. The AAO Annual Meeting is the world&#8217;s largest gathering of ophthalmologists and eye care professionals.<\/p><p><b>Eyecelerator Presentation Details:<\/b><\/p><p><b>Eyecelerator 2026, <\/b>Ernest N. Morial Convention Center<br \/><b>\u0644\u0648\u062d\u0629: <\/b>Emerging Innovations in Retinal Therapies<br \/><b>\u0627\u0644\u0645\u062a\u062d\u062f\u062b: <\/b>Sam Barone, MD, Chief Medical Officer<br \/><b>\u0627\u0644\u062a\u0627\u0631\u064a\u062e \u0648\u0627\u0644\u0648\u0642\u062a: <\/b>Thursday, October 8, 2026, 10:45\u201311:30 AM CT<br \/><b>\u0645\u0648\u0642\u0639: <\/b>La Nouvelle Ballroom C<\/p><p><b>Company Presentation: <\/b>Retina Drug Delivery &amp; New Targets Showcase<br \/><b>\u0645\u0642\u062f\u0645: <\/b>Paul Hallen, Chief Operating Officer<br \/><b>\u0627\u0644\u062a\u0627\u0631\u064a\u062e \u0648\u0627\u0644\u0648\u0642\u062a: <\/b>Thursday, October 8, 2026, 1:00\u20131:05 PM CT<br \/><b>\u0645\u0648\u0642\u0639: <\/b>Rooms 252\u2013254<\/p><p><b>AAO Presentation Details:<\/b><\/p><p><b>AAO 2026 Annual Meeting, <\/b>Ernest N. Morial Convention Center<b><br \/><\/b><strong>\u0639\u0631\u0636 \u062a\u0642\u062f\u064a\u0645\u064a<\/strong>: Lasting vision Improvement in Retinitis Pigmentosa: REMAIN 4-Year Study Data From the RESTORE Phase 2b\/3 Trial of MCO-010 Optogenetic Therapy<br \/><b>\u062d\u0635\u0629: <\/b>PA044<br \/><b>\u0645\u0642\u062f\u0645: <\/b>Kenneth C. Fan, MD<br \/><b>\u0627\u0644\u062a\u0627\u0631\u064a\u062e \u0648\u0627\u0644\u0648\u0642\u062a: <\/b>Sunday, October 11, 2026, 11:42\u201311:49 AM CT<br \/><b>\u0645\u0648\u0642\u0639: <\/b>Rooms 255\u2013257<\/p><p><b>Scientific Poster: <\/b>Vision Improvement in Dry AMD With Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 RCT<br \/><b>\u062d\u0635\u0629: <\/b>PO624<br \/><b>\u0645\u0642\u062f\u0645: <\/b>David S. Boyer, MD<br \/><b>Availability: <\/b>On demand<\/p><p>During the panel, Dr. Barone will join fellow industry leaders to discuss emerging approaches in retinal therapeutics, including the potential of mutation-agnostic optogenetic gene therapy for patients with advanced retinal degeneration. In the Showcase presentation, Mr. Hallen will provide an update on Nanoscope&#8217;s progress toward potential global approval of its lead asset, MOGENRY<sup>\u00ae<\/sup>\u00a0(<i>\u0633\u0648\u0646\u0628\u064a\u0631\u064a\u062a\u064a\u062c\u064a\u0646\u064a \u0625\u0633\u062a\u064a\u0628\u0627\u0631\u0641\u0648\u0641\u064a\u0643<\/i>; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the <a href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">Company&#8217;s Biologics License Application (BLA),<\/a>\u00a0\u0648 <a href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/01\/nanoscope-therapeutics-announces-pmda-acceptance-and-priority-review-of-new-drug-application-for-mogenry-in-japan-for-the-treatment-of-inherited-retinal-dystrophies\/\" target=\"_blank\" rel=\"nofollow noopener\">Japan New Drug Application (JNDA),<\/a>\u00a0<u>currently under FDA<\/u>\u00a0and PMDA<u> review<\/u>\u00a0respectively. At AAO 2026, Dr. Fan will present four-year data from the REMAIN study of patients treated in the RESTORE Phase 2b\/3 trial, highlighting the durability of vision improvement with MCO-010 in retinitis pigmentosa. Dr. David S. Boyer will also present a scientific poster, available on demand, on vision improvement with sonpiretigene isteparvovec in dry AMD from the first direct-to-Phase 2 randomized controlled trial. Members of the Nanoscope leadership team will be available to meet with retina specialists, investors, and potential partners throughout Eyecelerator and AAO 2026.<\/p><p>Nanoscope team members will be available at Booth 2564 for the duration of the AAO conference.<\/p><p><b>\u062d\u0648\u0644 MOGENRY (sonpiretigene isteparvovec\u061b MCO-010)<\/b><\/p><p>Nanoscope&#8217;s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope&#8217;s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope&#8217;s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan. The 2026 Nobel Prize in Physiology or Medicine was recently awarded to the three scientists who pioneered optogenetics, the scientific foundation that Nanoscope&#8217;s development programs, including MOGENRY, are built upon.<\/p><p><b>\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633<\/b><\/p><p>\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c \u0628\u0635\u0631\u064a \u0648\u0631\u0627\u062b\u064a \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0646\u0648\u0639 \u0627\u0644\u0645\u0631\u0636\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0630\u0644\u0643 \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0627\u0644\u062a\u064a \u062d\u0642\u0642\u062a\u0647\u0627 \u062a\u062c\u0631\u0628\u0629 RESTORE \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0627\u0644\u0645\u0636\u0628\u0648\u0637\u0629 \u0628\u0627\u0644\u063a\u0641\u0644\u060c \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2\u0628\/3\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP).<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>)\u060c \u0627\u0644 <a href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">FDA has accepted and filed the Company&#8217;s BLA for MOGENRY<\/a>, and the <a href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/01\/nanoscope-therapeutics-announces-pmda-acceptance-and-priority-review-of-new-drug-application-for-mogenry-in-japan-for-the-treatment-of-inherited-retinal-dystrophies\/\" target=\"_blank\" rel=\"nofollow noopener\">PMDA has accepted for priority review the Company&#8217;s NDA for MOGENRY for the treatment of IRDs in Japan<\/a>. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u0648\u062a\u062e\u0637\u0637 \u0627\u0644\u0634\u0631\u0643\u0629 \u0644\u0628\u062f\u0621 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u062a\u0633\u062c\u064a\u0644 \u0641\u064a \u0639\u0627\u0645 2026. \u0648\u0642\u062f \u062d\u0635\u0644 \u062f\u0648\u0627\u0621 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0643\u0644 \u0645\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) \u0648\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 (SD)\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 RMAT \u0644\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) \u0627\u0644\u062a\u064a \u062a\u063a\u0637\u064a \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u063a\u064a\u0631 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0648\u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0627\u0644\u0630\u064a \u064a\u0647\u064a\u0645\u0646 \u0641\u064a\u0647 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0639\u0635\u0648\u064a\u0629 \u0648\u0627\u0644\u0645\u062e\u0631\u0648\u0637\u064a\u0629\u060c \u0641\u0636\u0644\u0627\u064b \u0639\u0646 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621. \u0643\u0645\u0627 \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0633\u0627\u0643\u064a\u063a\u0627\u0643\u064a \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0641\u064a \u0627\u0644\u064a\u0627\u0628\u0627\u0646\u060c \u0648\u062a\u0635\u0646\u064a\u0641 \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0641\u064a \u0627\u0644\u0645\u0645\u0644\u0643\u0629 \u0627\u0644\u0639\u0631\u0628\u064a\u0629 \u0627\u0644\u0633\u0639\u0648\u062f\u064a\u0629. \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u0646 \u064a\u0628\u062f\u0623 \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u062f\u0648\u0627\u0621 MCO \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a \u0641\u064a \u0639\u0627\u0645 2026\u060c \u0648\u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0627\u0644\u0623\u062e\u0631\u0649 \u0627\u0644\u062c\u0627\u0647\u0632\u0629 \u0644\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u062c\u062f\u064a\u062f\u0629 (IND) \u0639\u0644\u0627\u062c \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631 (LCA).<\/p><p>Learn more at <a href=\"http:\/\/nanostherapeutics.com\/ar\/\" target=\"_blank\" rel=\"nofollow noopener\">NanosTherapeutics.com<\/a>\u00a0and follow @NSTherapeutics\u00a0on X and on LinkedIn.<\/p><p><b>\u0627\u062a\u0635\u0627\u0644:<\/b><\/p><p>\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633<br \/>(817) 857-1186<br \/><u><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><br \/><br \/><\/u>\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY\u00aein the Retina Drug Delivery New Targets Showcase at Eyecelerator 2026. Four-year REMAIN data from the RESTORE Phase 2b\/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10349,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-06T11:40:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-06T11:53:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting\",\"datePublished\":\"2026-10-06T11:40:29+00:00\",\"dateModified\":\"2026-10-06T11:53:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/\"},\"wordCount\":947,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_AAO_2026_feature.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_AAO_2026_feature.jpg\",\"datePublished\":\"2026-10-06T11:40:29+00:00\",\"dateModified\":\"2026-10-06T11:53:10+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_AAO_2026_feature.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_AAO_2026_feature.jpg\",\"width\":917,\"height\":916},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/10\\\/06\\\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - Nanoscope Therapeutics","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-10-06T11:40:29+00:00","article_modified_time":"2026-10-06T11:53:10+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Wilson PJ","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"5 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting","datePublished":"2026-10-06T11:40:29+00:00","dateModified":"2026-10-06T11:53:10+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/"},"wordCount":947,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_AAO_2026_feature.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/","name":"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_AAO_2026_feature.jpg","datePublished":"2026-10-06T11:40:29+00:00","dateModified":"2026-10-06T11:53:10+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_AAO_2026_feature.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_AAO_2026_feature.jpg","width":917,"height":916},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/10\/06\/nanoscope-therapeutics-to-participate-in-eyecelerator-2026-and-the-american-academy-of-ophthalmology-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u0648\u064a\u0644\u0633\u0648\u0646 \u0628\u064a \u062c\u064a\u0647"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=10348"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10348\/revisions"}],"predecessor-version":[{"id":10353,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10348\/revisions\/10353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/10349"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=10348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=10348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=10348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}